By combining a stalled toll-like receptor 9 (TLR9) agonist that advanced to Phase II in multiple cancer types at Dynavax Technologies Corporation with its own pressure-based drug delivery technology, TriSalus Life Sciences thinks it can provide add-on therapy that will reach deep into tumor vasculature and enhance the benefits of immuno-oncology agents in difficult-to-treat liver and pancreatic cancer settings.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?